Therefore, transgelin-2 is also a primary therapeutic target for which inhibition may restore the sensitivity of drug-resistant cancers (Nohata et al., 2011a,b; Kawakami et al., 2012; Moriya et al., 2012; Yoshida et al., 2013; Cai et al., 2014a,b; Xiao et al., 2014; Du et al., 2016). The gene discussed is TAGLN2; the disease is cancer.